WE-868 / Aardvark Therap - LARVOL DELTA

An Isoflavonoid Modulator of Oxidative Metabolism With Therapeutic Potential in Obesity and Diabetes (OBESITY WEEK 2025) - P1 | "WE-868 drives substantial weight loss in cancer patients and reverses diet-induced obesity and hyperglycemia in preclinical models. Its unique mechanism, characterized by suppression of mitochondrial respiration coupled with a glycolytic shift—all without mitochondrial uncoupling—positions WE-868 as a promising therapeutic candidate for metabolic disorders, and supports further evaluation for treating obesity and related comorbidities."

Colorectal Cancer • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Solid Tumor

WE-868 Obesity Program (GlobeNewswire) - "In preclinical studies, WE-868 dose-dependently prevented high-fat diet (HFD)-induced weight gain, with the higher dose inducing net weight loss; In DIO mice, significant weight loss was seen in medium and high dose WE-868 compared to semaglutide."

Preclinical • Obesity

Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek (The Manila Times) - "Aardvark will be hosting an investor webinar on Wednesday, November 5, 2025 from 5:00 to 7:00 p.m. ET. Aardvark will provide an overview of ARD-101, ARD-201 and WE-868 data presented at ObesityWeek, feature a discussion with key opinion leaders in obesity drug development, and provide a discussion on ARD-101 in Prader-Willi Syndrome (PWS) with guests from Prader-Willi Syndrome Association - USA."

Preclinical • Diabetes • Obesity • Prader–Willi syndrome